Edgewise Therapeutics Inc EWTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EWTX is a good fit for your portfolio.
News
-
Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies
-
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
-
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
-
Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
-
Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024
-
Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference
-
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
-
Edgewise Shares Rise Premarket on FDA Fast-Track Designation
Trading Information
- Previous Close Price
- $15.65
- Day Range
- $15.60–16.11
- 52-Week Range
- $5.14–20.65
- Bid/Ask
- $15.88 / $15.99
- Market Cap
- $1.49 Bil
- Volume/Avg
- 171,056 / 742,226
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 88
- Website
- https://www.edgewisetx.com
Comparables
Valuation
Metric
|
EWTX
|
DYN
|
PLRX
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.33 | 16.75 | 1.59 |
Price/Sales | — | — | 468.26 |
Price/Cash Flow | — | — | — |
Price/Earnings
EWTX
DYN
PLRX
Financial Strength
Metric
|
EWTX
|
DYN
|
PLRX
|
---|---|---|---|
Quick Ratio | 18.98 | 2.41 | 17.43 |
Current Ratio | 19.50 | 2.53 | 17.72 |
Interest Coverage | — | — | −145.34 |
Quick Ratio
EWTX
DYN
PLRX
Profitability
Metric
|
EWTX
|
DYN
|
PLRX
|
---|---|---|---|
Return on Assets (Normalized) | −24.36% | −88.69% | −22.68% |
Return on Equity (Normalized) | −25.87% | −114.25% | −24.50% |
Return on Invested Capital (Normalized) | −29.82% | −102.56% | −28.46% |
Return on Assets
EWTX
DYN
PLRX
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rmyzskys | Ksdh | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Tdsmlrgr | Chcjszk | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Gfljkxpvl | Fgkzb | $99.6 Bil | |
MRNA
| Moderna Inc | Bqrcxflh | Gpw | $38.8 Bil | |
ARGX
| argenx SE ADR | Ctndlzn | Cfdf | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Prdscmzx | Zsth | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Tpyhflcg | Wtywpd | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Mjxwjvb | Sfpkrlb | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Pxlnsmgnr | Kbprvb | $12.4 Bil | |
INCY
| Incyte Corp | Hwfwjcwcx | Zdtjng | $11.9 Bil |